Private label expansion Velocity Pharma is moving into a new vertical, Primacure Ventures, focused on a portfolio of 8 to 10 oral solid dosage prescription products to be launched in 3-9 months, signaling potential cross-sell opportunities to existing private label relationships and channel partners.

OTC manufacturing strength With a history of supplying over-the-counter products in multiple dosage forms to top retail chains, Velocity Pharma has established capabilities that can be leveraged to expand into additional OTC or preventive health lines for new and existing clients.

Strategic partnerships Recent collaboration with Cardinal Health highlights the company’s access to large distribution networks, suggesting sales opportunities through Cardinal Health channels and related wholesale pharmacy partners for both current and new products.

Quality and risk Past FDA-related recall reports and eye drops incidents indicate a need to emphasize robust quality systems in pitches, while presenting remediation and compliance capabilities as a competitive differentiator to risk-averse buyers.

Growth and scale Revenue in the low millions with a lean team indicates high potential for scalable partnerships, white-label or private-label manufacturing agreements, and accelerated onboarding for new product launches and contract manufacturing programs.